Multicenter Selective Lymphadenectomy Trial (MSLT)

Melanoma Clinical Trial

Official title:

A Clinical Study of Wide Excision Alone Versus Wide Excision With Intraoperative Lymphatic Mapping and Selective Lymph Node Dissection in the Treatment of Patients With Cutaneous Invasive Melanoma.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00275496
• Other study ID #: MSLT-1
• Secondary ID: NIH P01 CA029605
• Status: Completed
• Phase: Phase 3
• First received: January 10, 2006
• Last updated: September 1, 2015
• Start date: November 1993
• Est. completion date: June 2012

Study information

• Verified date: May 2014
• Source: John Wayne Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Subjects must be diagnosed with melanoma. All subjects receive Wide Excision (WEX) of their melanoma. If the melanoma meets study requirements, the subject is randomized to receive either (1) no further surgical procedures as part of the study or (2) a Selective Lymphadenectomy with the possibility of a Complete Lymphadenectomy. Subjects are then followed for 10 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2001
• Est. completion date: June 2012
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. The patient consents to be in the study.

2. The patient must have invasive melanoma with: 1) Clark Level III and Breslow Thickness greater than or equal to 1.00 mm; or 2) Clark Level IV or V with any Breslow thickness. A confirmation of diagnosis and thickness must be made by the institutional pathologist.

3. The primary cutaneous melanoma site must be on the head, neck, trunk, extremity, scalp, palm of the hand, sole of the foot, or subungual skin.

4. The patient's biopsy must have been completed no more than 10 weeks before the initial visit to the clinic. (Surgery must be scheduled within three months of the biopsy.)

5. The patient must be between 18 and 75 years old.

6. The patient must have a life expectancy of at least 10 years from the time of diagnosis, excluding the diagnosis of melanoma.

Exclusion Criteria:

1. The patient had a prior wide excision of the primary with a diameter of excision greater than or equal to 3.0 cm and the shortest margin from the tumor edge to the excision edge was measured by a pathologist to be greater than or equal to 1.5 cm; or the patient had an elliptical excision and a margin beyond the tumor edge was greater than or equal to 1.5 cm at the narrowest margin.

2. The primary cutaneous melanoma involves the eye, ear, mucous membranes.

3. The patient has clinical evidence of satellite lesions, in-transit, regional nodal or distant metastases.

4. The patient has a second primary invasive melanoma.

5. The patient has had any type of solid tumor or hematologic malignancy during the past 5 years. Exceptions are if the patient has been treated for T1 lesions (e.g., squamous cell carcinoma of the skin, basal cell carcinoma or in situ carcinoma of the uterine cervix) during the past 5 years, but has not received treatment within the last 6 months.

6. The patient has had prior skin grafts, tissue transfers or flaps, or lymph node dissections that may alter the lymphatic drainage pattern from a primary cutaneous melanoma to the adjacent regional lymph node basins.

7. The patient has had previous chemotherapy, immunotherapy or radiation therapy.

8. The patient has had an organ transplantation and is receiving immunosuppressive agents as a result of the transplantation.

9. The patient has taken oral or parenteral steroids or immunosuppressive drugs within the last 6 months.

10. The patient has any known primary or secondary immune deficiencies.

11. The patient has another medical condition that will affect life expectancy.

12. The patient is pregnant.

13. Evidence that the patient cannot undergo selective lymph node dissection for any reason.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Melanoma

Intervention

Procedure:
• Sentinel Lymph Node Dissection
Subject has wide excision and sentinel lymph node dissection for primary melanoma.
• Complete Lymph Node Dissection
Subject has wide excision, sentinel lymph node dissection, and complete lymph node dissection (if positive sentinel node found) for primary melanoma.
• Wide Excision
Subject has wide excision only for primary melanoma.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
John Wayne Cancer Institute	National Institutes of Health (NIH)

References & Publications (3)

Faries MB, Thompson JF, Cochran A, Elashoff R, Glass EC, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Wang HJ, Morton DL; MSLT Cooperative Group. The impact on morbidity and length of stay of early versus delayed — View Citation

Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Roses DF, Sondak VK, Reintgen DS, Kashani-Sabet M, Karakousis CP, Coventry BJ, Kraybill WG, Smithers BM, Elashoff R, Stern SL, Cochran AJ, Faries MB, Morton DL. Metastasectomy for distant metasta — View Citation

Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Glass EC, Wang HJ; MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006 Sep 2 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine whether wide excision of the primary with intraoperative lymphatic mapping (LM) followed by selective lymphadenectomy will effectively prolong overall survival compared to wide excision of the primary melanoma alone.		10 years	No
Secondary	Disease-free survival; Incidence, timing, and anatomic distribution of distant metastases; Morbidity of procedures; Significance of TA90 levels; Incidence of Sentinel Node Metastases (biopsy) vs clinical metastases (observation); Accuracy of LM		10 years	Yes

External Links

•   Link